News
Pharmaceutical Technology on MSN1d
Manufacturing issues at Novo facility disrupt Regeneron drug review
R egeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects ...
Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, ...
Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...
Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...
Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...
RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
The FDA issued a Complete Response Letter for Regeneron’s biologics license application for odronextamab, a bispecific antibody targeting CD20 and CD3 for the treatment of relapsed or refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback